SANOREX
LOE ApproachingNDAORALTABLET
Approved
Jun 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANOREX is an oral small-molecule tablet approved by Novartis in 1973 for an undisclosed indication. The mechanism of action and pharmacologic class are not publicly detailed in available sources. It remains an active pharmaceutical product despite its vintage approval date.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting brand team focus is shifting toward lifecycle management and generic transition strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SANOREX currently shows zero linked job openings, reflecting its mature lifecycle stage and approaching LOE. Career roles on this product are primarily commercial maintenance and regulatory stewardship rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on SANOREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.